Please login to the form below

Not currently logged in

Advodart with tamsulosin reduces AUR risk

Data shows that GSK's Avodart and tamsulosin combination treatment reduces the risk of acute urinary retention

Final results from the four-year GlaxoSmithKline (GSK)-sponsored Combination therapy with Avodart and tamsulosin (CombAT) study show that GSK's Avodart (dutasteride) and tamsulosin combination treatment reduces the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia (BPH)-related surgery, as well as reduced the risk of BPH clinical progression more than tamsulosin alone. Combination treatment also delivered superior, sustained symptom improvement from month nine compared to either dutasteride or tamsulosin monotherapy. 

A 66 per cent reduction in the risk of AUR or BPH-related surgery was achieved with combination treatment compared to tamsulosin (p<0.001) and there was a 20 per cent reduction compared to dutasteride (p=0.18). The risk of BPH clinical progression with combination treatment was reduced by 44 per cent, compared to tamsulosin and 31 per cent for those on dutasteride. 

The combination therapy was generally well tolerated, with erectile dysfunction and retrograde ejaculation the most commonly reported drug-related adverse events. The incidence of heart failure was however higher in the combination (0.9 per cent) and tamsulosin (0.6 per cent) than in the dutasteride group (0.2 per cent). There was no difference in overall cardiovascular events across treatment groups. 

Affecting 50 per cent of men over 50 years old, BPH is not life-threatening, but if left untreated, can lead to AUR, a complete obstruction of urinary excretion and BPH-related surgery.

12th October 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...